A once-daily pill without fasting restrictions could make a powerful class of diabetes and obesity drugs easier to use ...
Retatrutide, a triple action treatment for type 2 diabetes, could significantly reduce blood glucose concentrations and body ...
Over the past few years, GLP-1 drugs have transformed the treatment landscape for obesity and type 2 diabetes. By mimicking a ...
But with GLP-1 drugs, she said, “everyone is kind of iterating in real time.” Here’s what we’ve learned in the process. At ...
Eli Lilly shares gained on Monday, after a late-stage trial of its next-generation weight-loss drug impressed analysts.
For many people with type 2 diabetes, the problem is not just finding a drug that works. It is finding one they can ...
AstraZeneca’s experimental GLP-1 pill cut body weight by nearly 12% in obese patients over 36 weeks and reduced A1C, a metric ...
Objective: To compare the real-world effects of weekly injectable semaglutide (Ozempic) vs dulaglutide (Trulicity) on weight ...
Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide), today announced detailed results from three Phase 3 ...
So, how does Victoza compare to other GLP-1 medications, including semaglutide or tirzepatide? Here’s what you need to know ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results